Key result
Hypertrophic cardiomyopathy during pregnancy is linked to ~17.1-fold higher maternal mortality versus the general population.
Why the study?
The risk associated with pregnancy in women with HCM is an increasingly frequent clinical issue for which systematic data were unavailable and substantial uncertainty persisted.
Does pregnancy in women with hypertrophic cardiomyopathy increase maternal mortality and morbidity compared with the general population?
Cohort (n=100)
Does pregnancy in women with hypertrophic cardiomyopathy increase maternal mortality and morbidity compared with the general population?
Although maternal mortality in women with hypertrophic cardiomyopathy is higher than in the general population, absolute mortality is low and largely confined to high-risk or previously symptomatic women.
Answers are grounded in this paper and cite their sources.
Individualized pregnancy counseling remains essential in hypertrophic cardiomyopathy; leaves open need for prospective multicenter registries.
Objectives We sought to assess mortality and morbidity in pregnant women with hypertrophic cardiomyopathy (HCM). Background The risk associated with pregnancy in women with HCM is an important and increasingly frequent clinical issue for which systematic data are not available and a large measure of uncertainty persists. Methods Maternal mortality in 91 consecutively evaluated families with HCM was compared with that reported in the general population. The study cohort included 100 women with HCM with one or more live births, for a total of 199 live births. Morbidity related to HCM during pregnancy was investigated in 40 women evaluated within five years of their pregnancy. Results Two pregnancy-related deaths occurred, both in patients at a particularly high risk. The maternal mortality rate was 10 per 1,000 live births (95% confidence interval [CI] 1.1 to 36.2/1,000) and was in excess of the expected mortality in the general Italian population (relative risk 17.1, 95% CI 2.0 to 61.8). In the 40 patients evaluated within close proximity of their pregnancy, 1 (4%) of the 28 who were previously asymptomatic and 5 (42%) of the 12 with symptoms progressed to functional class III or IV during pregnancy (p < 0.01). One patient had atrial fibrillation and one had syncope, both of whom had already experienced similar and recurrent events before their pregnancy. Conclusions Maternal mortality is increased in patients with HCM compared with the general population. However, absolute maternal mortality is low and appears to be principally confined to women at a particularly high risk. In the presence of a favorable clinical profile, the progression of symptoms, atrial fibrillation, and syncope are also uncommon during pregnancy.
No takes yet. Share an insight, caveat, or question.
Autore et al. (2002) conducted a cohort in Hypertrophic cardiomyopathy (HCM) in pregnancy (n=100). Pregnancy in women with hypertrophic cardiomyopathy vs. General Italian population was evaluated on Maternal mortality rate per 1,000 live births (RR 17.1, 95% CI 2.0-61.8). Pregnancy in women with hypertrophic cardiomyopathy was associated with increased maternal mortality compared with the general population.
Synapse has enriched 10 related papers. Consider them for comparative context: